Maze Therapeutics adds two directors, grants 36K options

Maze Therapeutics, Inc. announced that its Board appointed Paula A. Johnson, M.D., M.P.H. as a Class III director and Sophie Kornowski, Pharm.D. as a Class I director, effective August 13, 2026.

Rhea-AI Filing Summary

Maze Therapeutics, Inc. announced that its Board appointed Paula A. Johnson, M.D., M.P.H. as a Class III director and Sophie Kornowski, Pharm.D. as a Class I director, effective August 13, 2026. Dr. Johnson’s term runs to the 2028 annual stockholders’ meeting and Dr. Kornowski’s to 2029, each continuing until a successor is elected or earlier departure events occur. Dr. Johnson joins the nominating and corporate governance committee, while Dr. Kornowski joins the audit and compensation committees.

Each new non-employee director receives compensation under Maze’s director policy, including a pro rata portion of the $40,000 annual cash retainer plus applicable committee retainers and an option to purchase 36,000 shares of common stock, vesting in equal monthly installments over 36 months from the appointment date. The Board also reclassified existing directors Nancy C. Andrews, M.D., Ph.D. and Hervé Hoppenot between Class II and Class III to rebalance the three director classes, with revised terms expiring at the 2027 and 2028 annual meetings, respectively.

8-K Event Classification

3 items: 5.02, 7.01, 9.01

3 items

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers Governance

Key personnel changes including departures, elections, or appointments of directors and executive officers.

Item 7.01 Regulation FD Disclosure Disclosure

Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, or exhibit attachments filed with this report.

Key Figures

Annual director cash retainer: $40,000 Option shares per new director: 36,000 shares Option vesting schedule: 1/36 per month +5 more

8 metrics

Annual director cash retainer $40,000 Annual cash retainer for non-employee directors under the Director Compensation Policy

Option shares per new director 36,000 shares Stock option granted to each of Paula Johnson and Sophie Kornowski on August 13, 2026

Option vesting schedule 1/36 per month One thirty-sixth of each 36,000-share option vests monthly from the Appointment Date

Paula Johnson age 66 Age of Dr. Paula Johnson at the time of appointment as director

Sophie Kornowski age 63 Age of Dr. Sophie Kornowski at the time of appointment as director

Term end Class III (Johnson) 2028 Dr. Johnson’s director term scheduled to expire at the 2028 annual meeting

Term end Class I (Kornowski) 2029 Dr. Kornowski’s director term scheduled to expire at the 2029 annual meeting

Press release date August 13, 2026 Date of the press release announcing the new board appointments

Key Terms

Class I director, Class III director, Regulation FD Disclosure, APOL1-mediated kidney disease (AMKD), +2 more

6 terms

Class I director regulatory

"appointed Paula A. Johnson, M.D., M.P.H. as a Class III director and Sophie Kornowski, Pharm.D. as a Class I director"

A class I director is a member of a company’s board who belongs to one of several groups whose terms expire in a specified year under a staggered election system; each class is elected on a different cycle so only a portion of the board faces re-election each year. This matters to investors because it affects how quickly control of the board can change, the company’s continuity and oversight, and the ease of mounting or defending against takeover efforts—think of a team where only some players are replaced each season rather than the whole roster at once.

Class III director regulatory

"appointed Paula A. Johnson, M.D., M.P.H. as a Class III director and Sophie Kornowski, Pharm.D. as a Class I director"

A Class III director is a board member placed in one of the numbered groups used by companies with a staggered (or “classified”) board; that director’s seat typically comes up for election in the third year of a three-year rotation. For investors this matters because staggered terms create continuity but also make it harder to replace the whole board quickly, affecting shareholder influence, takeover dynamics and how fast new strategy or accountability can be implemented — like replacing only some players on a sports team each season instead of the whole roster at once.

Regulation FD Disclosure regulatory

"Item 7.01 Regulation FD Disclosure. On August 13, 2026, the Company issued a press release"

Regulation FD disclosure requires public companies to share important, market-moving information with everyone at the same time instead of tipping off analysts or large investors first. Think of it as making sure all players on a field hear the same announcement simultaneously; that fairness helps investors trust that stock prices reflect the same information and reduces the risk of sudden, unfair trading advantages or regulatory penalties for selective leaks.

APOL1-mediated kidney disease (AMKD) medical

"MZE829, a dual-mechanism APOL1 inhibitor in Phase 2 development for APOL1-mediated kidney disease (AMKD)"

Apol1-mediated kidney disease (AMKD) is kidney damage driven by inherited changes in the APOL1 gene that substantially increase the risk of chronic kidney disease and faster progression to kidney failure, most often seen in people of West African descent. It matters to investors because these genetic drivers define a clear patient subgroup, shaping demand for targeted tests and therapies, influencing clinical trial design and regulatory strategy, and helping estimate market size—like a faulty blueprint that predicts who will need specific medical solutions.

phenylketonuria (PKU) medical

"MZE782, a SLC6A19 inhibitor in Phase 2 development with the potential to treat both phenylketonuria (PKU)"

A genetic metabolic disorder in which the body cannot break down the amino acid phenylalanine, causing it to build up and potentially damage the brain if untreated; newborn screening and lifelong management are common. Investors care because the condition creates steady demand for diagnostic tests, specialized diets and medical treatments, and because regulatory approvals, reimbursement rules and advances in therapy can materially affect market size and company revenues—think of it like a clogged drain that needs ongoing tools and fixes.

chronic kidney disease (CKD) medical

"MZE782, a SLC6A19 inhibitor in Phase 2 development with the potential to treat both phenylketonuria (PKU) and chronic kidney disease (CKD)"

Chronic kidney disease (CKD) is a long-term decline in the kidneys’ ability to filter waste and balance fluids and chemicals in the body, often progressing slowly over months or years; think of it as a filter that gradually becomes clogged and less effective. It matters to investors because CKD drives demand for drugs, dialysis, transplants, diagnostics and related medical devices, influences healthcare costs and reimbursement decisions, and is a common target for clinical trials and regulatory review.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What board appointments did Maze Therapeutics (MAZE) announce on August 13, 2026?

Maze Therapeutics appointed Paula A. Johnson as a Class III director and Sophie Kornowski as a Class I director, both effective August 13, 2026. They also received committee assignments on nominating and governance, audit, and compensation committees.

What equity awards did the new Maze Therapeutics (MAZE) directors receive?

Each of Paula Johnson and Sophie Kornowski received an option to purchase 36,000 shares of Maze common stock. The options vest monthly over 36 months from the appointment date, conditioned on continued service as directors.

How are the new Maze Therapeutics (MAZE) directors compensated in cash?

Each new non-employee director is entitled to a pro rata portion of a $40,000 annual cash retainer for board service for the remainder of the year, plus any applicable committee retainers, consistent with Maze’s non-employee director compensation policy.

How did Maze Therapeutics (MAZE) change its board class composition?

To keep each director class near one-third of the Board, Maze moved Nancy C. Andrews from Class III to Class II and Hervé Hoppenot from Class II to Class III, with new terms expiring at the 2027 and 2028 annual meetings, respectively.

What upcoming clinical milestones did Maze Therapeutics (MAZE) highlight in its press release?

Maze highlighted additional data from MZE829 in broad AMKD patients expected in late 2026 or early 2027, initial data from MZE782 in 2027, and further trial initiations for both molecules in the following year.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 08/17/2026 - 04:16 PM EDT Learn about SEC filing dates

false 0001842295 0001842295 2026-08-13 2026-08-13

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 13, 2026

Maze Therapeutics, Inc.

(Exact name of Registrant as Specified in Its Charter)

Delaware		001-42490		82-2635018
(State or Other Jurisdiction of Incorporation)		(Commission File Number)		(IRS Employer Identification No.)

171 Oyster Point Blvd., Suite 300
South San Francisco, California		94080
(Address of Principal Executive Offices)		(Zip Code)

Registrant’s Telephone Number, Including Area Code: 650 850-5070

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock - par value $0.001 per share		MAZE		The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On August 13, 2026, the Board of Directors (the “Board”) of Maze Therapeutics, Inc. (the “Company”) appointed Paula A. Johnson, M.D., M.P.H. as a Class III director and Sophie Kornowski, Pharm.D. as a Class I director, in each case effective August 13, 2026 (the “Appointment Date”). Dr. Johnson will serve as a Class III director for a term expiring at the Company’s 2028 annual meeting of stockholders, and Dr. Kornowski will serve as a Class I director for a term expiring at the Company’s 2029 annual meeting of stockholders, in each case until such director’s successor is duly elected and qualified, or until such director’s earlier death, resignation, disqualification, retirement or removal.

The Board appointed Dr. Johnson to serve as a member of the nominating and corporate governance committee of the Board, and appointed Dr. Kornowski to serve as a member of the audit committee and the compensation committee of the Board, in each case effective as of the Appointment Date.

Dr. Johnson, age 66, has served as the President of Wellesley College since 2016. Prior to that, Dr. Johnson founded and served as the inaugural Executive Director of the Connors Center for Women’s Health and Gender Biology at Brigham and Women’s Hospital, a Harvard teaching hospital, and as Chief of the Division of Women’s Health at Brigham and Women’s Hospital, in each case from July 2002 to June 2016. She also served as the Grayce A. Young Family Professor of Medicine in Women’s Health at Harvard Medical School and as a Professor of Epidemiology at the Harvard T.H. Chan School of Public Health. Dr. Johnson has served as a member of the board of directors of Johnson & Johnson, a multinational healthcare company, since 2023, as a member of the board of trustees of The Rockefeller University since November 2021, and as a member of the board of directors of the Isabella Stewart Gardner Museum since 2015. She is a member of the National Academy of Medicine and the American Academy of Arts and Sciences. Dr. Johnson received her A.B., her M.P.H. and her M.D. from Harvard University. Our Board believes Dr. Johnson’s is qualified to serve on our Board due to her extensive leadership experience in academic medicine, public health and higher education.

Dr. Kornowski, age 63, most recently served as Chief Executive Officer of Boston Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, from 2022 to 2025, and as a member of its board of directors. From 2018 to 2025, Dr. Kornowski served as a Senior Partner at Gurnet Point Capital, a healthcare-focused investment firm. Prior to that, Dr. Kornowski served as Executive Vice-President and Head of Roche Partnering at F. Hoffmann-La Roche AG, a multinational healthcare company, and as a member of its Extended Corporate Executive Committee, and served as a member of the board of directors of Chugai Pharmaceutical Co., Ltd. Dr. Kornowski received a Doctorate in Pharmacy from Paris Descartes University and an M.B.A. from the University of Chicago Booth School of Business. Our Board believes Dr. Kornowski’s is qualified to serve on our Board due to her extensive executive, investment and business development experience in the global biopharmaceutical industry.

In connection with their respective appointments as non-employee directors of the Company, each of Dr. Johnson and Dr. Kornowski will receive compensation in accordance with the Company’s non-employee director compensation policy (the “Director Compensation Policy”), including a pro rata portion of the $40,000 annual cash retainer for service as a director for the remaining portion of the year, together with the applicable committee retainers. In addition, in accordance with the Director Compensation Policy, the Board granted to each of Dr. Johnson and Dr. Kornowski, effective as of the Appointment Date, an option to purchase 36,000 shares of the Company’s common stock (each, an “Option Award”), with 1/36th of the shares underlying each Option Award vesting and becoming exercisable on each monthly anniversary of the Appointment Date, subject to the applicable director’s continued service to the Company.

Except as described above, there are no arrangements or understandings between either of Dr. Johnson or Dr. Kornowski and any other persons pursuant to which she was selected as a member of the Board. No family relationships exist between either of Dr. Johnson or Dr. Kornowski and any of the Company’s directors or executive officers. Neither Dr. Johnson nor Dr. Kornowski has any direct or indirect material interest in any transaction required to be disclosed pursuant to Item 404(a) of Regulation S-K.

Changes to the Classes of the Board.

In connection with the foregoing appointments, on August 13, 2026, the Board approved changes to the composition of the classes of the Board so that, as nearly as possible, each class consists of one-third of the total number of directors, as contemplated by the Company’s amended and restated certificate of incorporation. To effect these changes in accordance with the requirements of the Delaware General Corporation Law and the Company’s amended and restated certificate of incorporation, effective August 13, 2026, Nancy C. Andrews, M.D., Ph.D. resigned from her position as a Class III director (with a term expiring at the Company’s 2028 annual meeting of stockholders), subject to and conditioned upon her immediate reappointment as a Class II director, and the Board accepted Dr. Andrews’ resignation and immediately reappointed her as a Class II director with a term expiring at the Company’s 2027 annual meeting of stockholders. Also effective August 13, 2026, Hervé Hoppenot resigned from his position as a Class II director (with a term expiring at the Company’s 2027 annual meeting of stockholders), subject to and conditioned upon his immediate reappointment as a Class III director, and the Board accepted Mr. Hoppenot’s resignation and immediately reappointed him as a Class III director with a term expiring at the Company’s 2028 annual meeting of stockholders.

Item 7.01 Regulation FD Disclosure.

On August 13, 2026, the Company issued a press release announcing the appointment of Dr. Johnson and Dr. Kornowski to the Board. The full text of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

The information in Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section or Section 11 or 12(a)(2) of the Securities Act of 1933, as amended (the “Securities Act”), nor shall it be deemed incorporated by reference into any filing by the Company under the Exchange Act or the Securities Act, whether made before or after the date hereof, except as expressly set forth by reference in such filing.

Item 9.01 Financial Statements and Exhibits.

Exhibit Number		Description
99.1		Press release, dated August 13, 2026.
104		Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: August 17, 2026				By:		/s/ Courtney Phillips
						Courtney Phillips General Counsel and Corporate Secretary

Exhibit 99.1

Maze Therapeutics Announces Appointments to Its Board of Directors

August 13, 2026

Paula Johnson, M.D., M.P.H., and Sophie Kornowski, Pharm.D., M.B.A., join Maze’s Board of Directors, adding to the Company’s deep bench of clinical and industry experience

SOUTH SAN FRANCISCO, Calif., Aug. 13, 2026 (GLOBE NEWSWIRE) -- Maze Therapeutics, Inc. (Nasdaq: MAZE), a clinical-stage biopharmaceutical company developing small molecule precision medicines for patients with kidney and metabolic diseases, today announced the appointments of Paula Johnson, M.D., M.P.H., and Sophie Kornowski, Pharm.D., M.B.A., to its Board of Directors.

“We are excited to welcome Paula and Sophie to our Board at this important time for our company. With key progress made in our development programs, we are looking ahead to several important milestones, including additional data from MZE829 in broad AMKD patients in late 2026 or early 2027, initial data from MZE782 in 2027, and additional trial initiations for both molecules next year,” said Jason Coloma, Ph.D., chief executive officer of Maze. “As we continue to advance Maze’s pipeline toward late-stage clinical development and pre-commercial planning, both Paula and Sophie will bring a wealth of clinical and business experience to support our mission to harness the power of genetics to transform the lives of patients.”

Dr. Johnson brings over 30 years of clinical and research experience, specializing in cardiology. She has served as President of Wellesley College since 2016 and currently serves on the Board of Directors of Johnson & Johnson (J&J). Previously, Dr. Johnson founded and served as the inaugural Executive Director of the Connors Center for Women’s Health and Gender Biology at Brigham and Women’s Hospital from 2002 to 2016, and served as the Chief of the Division of Women’s Health at Brigham and Women’s Hospital from 2002 to 2016. She previously served as a Clinical Epidemiologist at Brigham and Women’s Hospital, as a Professor of Medicine at Harvard Medical School, and as Professor of Epidemiology at the Harvard School of Public Health. She holds an M.D. from Harvard Medical School, an M.P.H. from the Harvard T.H. Chan School of Public Health, and an A.B. from Harvard.

Dr. Kornowski joins Maze’s Board of Directors with more than 35 years of biopharmaceutical leadership experience, most recently serving as Chief Executive Officer of Boston Pharmaceuticals beginning in 2022, focusing the company’s pipeline on candidates for liver disease and leading the company to its acquisition by GlaxoSmithKline (GSK). Previously, she served as a Senior Partner at Gurnet Point Capital. Dr. Kornowski was Executive Vice-President of Roche Partnering and a member of the Extended Corporate Executive Committee of F. Hoffmann-La Roche AG and a board member of Chugai Pharmaceuticals. In that role, she led partnering and M&A strategy across early-stage compounds, late-stage assets, and technology-driven biotech companies, working closely with R&D and Commercial teams at Roche and Genentech. Earlier in her career, she held several commercial leadership roles across geographies in leading innovative pharmaceutical and diagnostic companies in France, Israel, and the U.S., notably at Roche and Merck & Co. She holds a Pharm.D. from Paris Descartes University and an M.B.A. from the University of Chicago Booth School of Business.

About Maze Therapeutics

Maze Therapeutics is a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel small molecule precision medicines for patients with kidney and metabolic diseases. Guided by its Compass^™ platform, Maze pursues genetically validated targets by integrating variant discovery and functionalization to discover and advance small molecule programs with first- or best-in-class potential. Maze’s pipeline is led by MZE829, a dual-mechanism APOL1 inhibitor in Phase 2 development for APOL1-mediated kidney disease (AMKD), and MZE782, a SLC6A19 inhibitor in Phase 2 development with the potential to treat both phenylketonuria (PKU) and chronic kidney disease (CKD). Maze is headquartered in South San Francisco. For more information, please visit mazetx.com, or follow Maze on LinkedIn and X.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements reflect the current beliefs and expectations of management. All statements other than statements of historical fact are statements that could be deemed forward-looking statements, including, without limitation, statements concerning the company’s future plans and prospects, any expectations regarding the safety or efficacy of MZE829, MZE782 and other candidates under development, the ability of MZE829 to treat AMKD or other indications, the ability of MZE782 to treat PKU, CKD or other indications, the planned timing of the company’s clinical trials, data results and further development of MZE829, MZE782 and other therapeutic candidates, and the company’s ability to advance its pipeline towards late-stage clinical development. In addition, when or if used in this press release, the words “may,” “could,” “should,”

“anticipate,” “believe,” “estimate,” “expect,” “intend,” “plan,” “will,” “predict” and similar expressions and their variants, as they relate to the company may identify forward-looking statements. Forward-looking statements are neither historical facts nor assurances of future performance. Although the company believes the expectations reflected in such forward-looking statements are reasonable, the company can give no assurance that such expectations will prove to be correct. Readers are cautioned that actual results, levels of activity, safety, performance or events and circumstances could differ materially from those expressed or implied in the company’s forward-looking statements due to a variety of factors, including risks and uncertainties related to the company’s ability to advance MZE829, MZE782 and its other therapeutic candidates, obtain regulatory approval of and ultimately commercialize the company’s therapeutic candidates, the timing and results of preclinical studies and clinical trials, the company’s ability to fund development activities and achieve development goals, its ability to protect its intellectual property, general business and economic conditions, and risks related to the impact on its business of macroeconomic conditions, including inflation, volatile interest rates, tariffs, instability in the global banking sector, and public health crises. Further information on potential risk factors that could affect the company’s business and its financial results is detailed under the heading “Risk Factors” included in the documents the company files from time to time with the U.S. Securities and Exchange Commission, including the company’s Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. Accordingly, readers are cautioned not to place undue reliance on these forward-looking statements. These forward-looking statements speak only as of the date of this press release and the company undertakes no obligation to revise or update any forward-looking statements to reflect events or circumstances after the date hereof.

IR/Corporate Contact:

Argot Partners

maze@argotpartners.com

Media Contact:

Amanda Lazaro, 1AB Media

amanda@1ABMedia.com

Filing Exhibits & Attachments

4 documents

Press Releases

• EX-99.1 EX-99.1 10.9 KB

Other Documents

• EX-101 XBRL TAXONOMY EXTENSION SCHEMA 3.1 KB
• EX-101 XBRL TAXONOMY EXTENSION LABEL LINKBASE 18.3 KB
• EX-101 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE 11.4 KB